Related content

The blood option: transcriptional profiling in clinical trials

By Baird Alison E  

Pharmacogenomics, Vol. 7, Iss. 2, 2006-03 ,pp. : 141-144

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic data submissions to the FDA: clinical case studies

By Trepicchio William L   Williams Grant A   Essayan David   Hall Sue T   Harty Lea C   Shaw Peter M   Spear Brian B   Wang Sue Jane   Watson Mark L  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 519-524

Future Medicine

Access to resources Recommend Favorite

Transcriptional profiling in cancer: the path to clinical pharmacogenomics

By Slonim Donna K  

Pharmacogenomics, Vol. 2, Iss. 2, 2001-05 ,pp. : 123-136

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic data submissions to the FDA: non-clinical case studies

By Leighton John K   DeGeorge Joseph   Jacobson-Kram David   MacGregor James   Mendrick Donna   Worobec Alexandra  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 507-511

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies

By Ruañño Gualberto   Collins Jerry M   Dorner Andrew J   Wang Sue-Jane   Guerciolini Roberto   Huang Shiew-Mei  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 513-517

Future Medicine

Access to resources Recommend Favorite